A lesson in prevention that is also a sales pitch

VIIV HEALTHCARE, the HIV specialist majority owned by GSK, launched a new awareness campaign in June this year. The slogan, "PrEP Wisdom", sounds almost pastoral: a gentle encouragement for people to have better conversations with their doctors about long-acting injectable HIV prevention. TV presenter Michelle Visage lends her voice. The target is a genuine gap: roughly 2.2 million Americans could benefit from pre-exposure prophylaxis, yet only about a quarter are using it. The public-health case is sincere. The commercial one is harder to ignore.

The campaign is not a disguise for something shadier. PrEP, when taken as prescribed, reduces the risk of acquiring HIV through sex by approximately 99%, according to the US Department of Veterans Affairs. Long-acting injectable versions, which avoid the daily pill entirely, are a genuine advance. Education and de-stigmatisation around sexual-health prevention are worthy goals. ViiV, which has ranked first among all pharmaceutical companies in patient-group reputation for 13 consecutive years, has built its brand on patient engagement, and the campaign is consistent with that record.

But behind the civic tone lies a product battle of considerable size. ViiV's long-acting prevention injection, Apretude, based on cabotegravir, requires a shot every two months. Gilead Sciences, the other major player in the HIV franchise, has entered with lenacapavir, branded as Yeztugo in the United States, which is administered just twice a year. The "PrEP Wisdom" campaign is careful never to name the competition. Instead, it urges people to learn the "important differences" between injectable options and to "know what to ask their doctor" about where the injection is given, what interactions to expect, and what to anticipate before, during, and after the shot. The message is education. The effect is to steer patients toward the option ViiV already makes.

The financial stakes make the incentive plain. ViiV's HIV therapies generated roughly £5.5 billion ($7.4 billion) in the first nine months of 2025, out of total group sales of just over £24 billion, according to GSK's own disclosure. GSK is entitled to about 83% of ViiV's earnings, making the HIV unit one of the largest single profit centres in the parent company's portfolio. In April this year, Pfizer exited ViiV in a deal worth just over $2.1 billion, with Shionogi, a Japanese pharma firm, doubling its stake to 21.7%. The ownership is now simpler, but the commercial focus is sharper. GSK has said it aims to grow ViiV's sales to more than £7 billion this year.

To be sure, Gilead is no slouch. Its flagship daily pill Biktarvy set a record for HIV-drug sales in 2025, generating more than $10 billion in annual revenue. Gilead's lenacapavir for PrEP is newer and, with its twice-yearly schedule, arguably more convenient. And the company has its own patient-access programmes and marketing machine. The competition, in other words, is not between a charity and a profit-seeker. It is between two well-resourced companies, both of which want patients to move from daily pills to long-acting injections that they supply.

The trouble is that the market for these injections depends on a behaviour that the industry itself helped create. Daily PrEP has been available for more than a decade. Adoption remains stubbornly low, held back by stigma, inadequate provider training, and a health system that often treats sexual health as an afterthought. The companies that stand to profit most from the next generation of prevention are also the ones with the most to lose if patients never get on any PrEP at all. Hence the patient-education campaigns. Hence the celebrity advocates. Hence the helpful websites.

This is not a story about bad faith. The incentives are genuinely aligned: fewer HIV infections are better for public health and also expand the addressable population for both prevention and treatment products. ViiV's voluntary licensing with the Medicines Patent Pool has enabled generic dolutegravir to reach more than 26 million people across 129 countries, at least 90% of people on antiretrovirals in low- and middle-income countries where generics are accessible. The same company that sells expensive injections in rich markets also licenses its molecules to generic manufacturers in poor ones. The model is unusual in pharma, but it is coherent.

Where the analysis should be more cautious is in reading campaign rhetoric as a proxy for access. Education campaigns do not solve insurance gaps, provider shortages, or the structural inequities that keep PrEP utilisation low in communities of colour, particularly among Black women in the southern United States, who face the highest HIV incidence in the country. ViiV acknowledges these gaps in its own internal materials, yet the "PrEP Wisdom" framing places the onus on individual knowledge rather than on system design. Knowing more about injectable options does not help the patient whose nearest clinic does not stock them.

The second-order consequence worth watching is what happens when long-acting injections become the default. In treatment, ViiV is pushing Dovato, a two-drug daily regimen of dolutegravir and lamivudine, against Gilead's three-drug Biktarvy. ViiV is presenting head-to-head phase 3b data from the VOGUE trial at the AIDS 2026 conference in Rio this month, a direct challenge to Gilead's market leadership. The treatment and prevention franchises are converging. The company that wins patient habits in one is likely to gain an advantage in the other.

For investors in GSK, the lesson is not about slogans. It is about whether ViiV can defend its share of the long-acting franchise against Gilead's deeper pipeline and larger HIV revenue base. The ownership simplification with Pfizer's departure removes a complication from GSK's balance sheet. It also removes the possibility that Pfizer might have pivoted the company toward a different therapeutic area. GSK's bet is that HIV alone is worth the focus. So far the numbers support it. The risk is that convenience, not chemistry, decides the next cycle: Gilead's twice-yearly injection may be easier for patients to stick with than ViiV's bi-monthly one, regardless of which is the superior molecule.

Better prevention is desirable on its own terms. But patients who respond to "PrEP Wisdom" well enough to book an appointment are also, whether the campaign intends it or not, a pipeline for ViiV's next billion in sales. The public-health argument and the commercial one are not at war. They are, for now, pointing in the same direction. That alignment is the real news.